- Home
- FENC vs RPID Comparison
FENC vs RPID Comparison
Compare FENC & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | RPID |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 204.3M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FENC | RPID |
|---|---|---|
| Price | $9.69 | $1.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.50 | $8.00 |
| AVG Volume (30 Days) | ★ 257.1K | 152.3K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,642,000.00 | $33,587,000.00 |
| Revenue This Year | $65.12 | $19.12 |
| Revenue Next Year | $41.08 | $18.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $5.65 | $1.90 |
| 52 Week High | $10.27 | $4.94 |
Technical Indicators
Market Signals| Indicator | FENC | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 76.50 | 33.99 |
| Support Level | $7.45 | N/A |
| Resistance Level | $9.92 | $2.46 |
| Average True Range (ATR) | 0.61 | 0.16 |
| MACD | 0.35 | -0.05 |
| Stochastic Oscillator | 86.85 | 13.13 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.